Posted on 4 August 20252 September 2025 FDA approves Sanofi’s BTK inhibitor for immune thrombocytopenia Sanofi’s oral reversible Bruton’s tyrosine kinase (BTK) inhibitor, Wayrilz (rilzabrutinib), has secured approval from the US F...
